15,581 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. bought a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 15,581 shares of the medical research company’s stock, valued at approximately $5,119,000. Raymond James Financial Inc. owned 0.06% of Bio-Rad Laboratories as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Bio-Rad Laboratories by 1.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 441,098 shares of the medical research company’s stock valued at $147,583,000 after acquiring an additional 4,260 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in Bio-Rad Laboratories in the third quarter valued at $83,681,000. Charles Schwab Investment Management Inc. grew its position in Bio-Rad Laboratories by 4.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 191,867 shares of the medical research company’s stock worth $63,030,000 after purchasing an additional 7,552 shares during the period. Fisher Asset Management LLC raised its stake in shares of Bio-Rad Laboratories by 15.2% during the 4th quarter. Fisher Asset Management LLC now owns 106,871 shares of the medical research company’s stock valued at $35,108,000 after buying an additional 14,135 shares during the last quarter. Finally, Wedge Capital Management L L P NC acquired a new position in shares of Bio-Rad Laboratories in the 4th quarter valued at about $28,740,000. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Down 3.7 %

Shares of BIO stock opened at $247.16 on Wednesday. Bio-Rad Laboratories, Inc. has a 1-year low of $244.00 and a 1-year high of $387.99. The company has a market cap of $6.92 billion, a price-to-earnings ratio of -3.80 and a beta of 0.98. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85. The stock has a 50 day simple moving average of $299.43 and a 200-day simple moving average of $324.12.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. On average, equities research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BIO has been the subject of several recent research reports. Wells Fargo & Company reduced their price target on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. StockNews.com lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $481.00 price target on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $395.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.